Details Basic Details Status Ongoing Last Updated Thursday, December 7, 2023 Original Posting Date Wednesday, August 23, 2017 Health Outcome(s) hospitalized neutropenia, myocardial infarction and stroke, serious infection Purpose Drug and Outcome Analysis Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR Yes Result(s) (2) Utilization of Brodalumab: A Descriptive Analysis Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: An Updated Descriptive Analysis Regulatory Link(s) (1) FDA Approval Package Materials